Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Zai Lab (ZLAB) reported topline data from a Phase 3 study for KarXT in the treatment of schizophrenia, with plans to file for approval in China in early 2025. Read more here.

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China to treat schizophrenia. The registrational bridging trial, which ...

Zai Lab (ZLAB) presented data from the ongoing global Phase 1a/1b study of ZL-1310, a next-generation antibody-drug conjugate, or ADC, at the ...

Zai Lab Limited Unsponsored ADR (ZLAB) shares soared 14.7% in the last trading session to close at $33.18. The move was backed by solid volume with far more shares changing hands than in a normal ...

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The FDA approved KarXT for schizophrenia in September. The drug will ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the ...